Wall Street brokerages expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) to announce ($0.27) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aldeyra Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.22). Aldeyra Therapeutics reported earnings per share of ($0.25) during the same quarter last year, which suggests a negative year over year growth rate of 8%. The company is scheduled to report its next quarterly earnings results on Thursday, August 5th.
On average, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.28) to ($0.99). For the next year, analysts anticipate that the company will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.34) to ($1.12). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Wednesday, May 5th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.04.
In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 1,200,000 shares of the stock in a transaction that occurred on Monday, May 3rd. The shares were bought at an average price of $12.50 per share, for a total transaction of $15,000,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Diametric Capital LP bought a new stake in Aldeyra Therapeutics in the 1st quarter worth about $123,000. Millennium Management LLC grew its position in Aldeyra Therapeutics by 51.5% in the 1st quarter. Millennium Management LLC now owns 543,823 shares of the biotechnology company’s stock worth $6,461,000 after purchasing an additional 184,768 shares in the last quarter. First Light Asset Management LLC bought a new stake in Aldeyra Therapeutics in the 1st quarter worth about $31,173,000. D. E. Shaw & Co. Inc. bought a new stake in Aldeyra Therapeutics in the 1st quarter worth about $216,000. Finally, Verition Fund Management LLC grew its position in Aldeyra Therapeutics by 111.8% in the 1st quarter. Verition Fund Management LLC now owns 416,717 shares of the biotechnology company’s stock worth $4,951,000 after purchasing an additional 219,963 shares in the last quarter. 55.11% of the stock is owned by institutional investors and hedge funds.
ALDX traded up $0.06 during trading on Friday, reaching $12.47. 3,306 shares of the stock traded hands, compared to its average volume of 1,903,966. The company has a quick ratio of 13.26, a current ratio of 13.26 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $718.66 million, a PE ratio of -11.49 and a beta of 1.75. The company has a 50-day simple moving average of $12.12. Aldeyra Therapeutics has a 12 month low of $3.95 and a 12 month high of $15.95.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Read More: Preferred Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.